Fig. 5.

4.1B is down-regulated in aggressive TRAMP tumor cell lines and in human clinical prostate cancer. (A) 4.1B protein levels are reduced in malignant TRAMP-C1 cells (C1) relative to nonmalignant TRAMP-C3 cells (C3); independent replicate samples are shown. (B) 4.1B expression is significantly down-regulated during human clinical prostate cancer progression, from normal prostate tissue, to prostate cancer, and finally to prostate cancer lymph node metastases [data obtained by Lapointe et al. (22) and processed by Oncomine 3.0]. Three additional human clinical prostate cancer studies displaying down-regulation of 4.1B can be found in SI Fig. 17.